Find, compare & contact
Roflumilast API Manufacturers & Suppliers

Looking for Roflumilast API 162401-32-3?

Description:

Here you will find a list of producers, manufacturers and distributors of Roflumilast. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.

API | Excipient name:

Roflumilast 

Synonyms:

Daliresp , ROF , Roflumilastum  

Cas Number:

162401-32-3 

DrugBank number:

DB01656 

Unique Ingredient Identifier:

0P6C6ZOP5U

Roflumilast is a type of Phosphodiesterase-4 Inhibitors

Phosphodiesterase-4 (PDE-4) inhibitors belong to the subcategory of pharmaceutical active pharmaceutical ingredients (APIs) that are widely used in the treatment of various inflammatory and respiratory conditions. These inhibitors work by blocking the enzyme phosphodiesterase-4, which is responsible for breaking down cyclic adenosine monophosphate (cAMP) in cells. By inhibiting PDE-4, the levels of cAMP are increased, leading to reduced inflammation and bronchoconstriction.

PDE-4 inhibitors have shown significant therapeutic potential in the management of chronic obstructive pulmonary disease (COPD), asthma, and psoriasis. The most commonly prescribed PDE-4 inhibitor is roflumilast, which is available in oral tablet form. Roflumilast specifically targets lung tissue and effectively reduces airway inflammation and hyperresponsiveness, improving lung function and reducing exacerbations in COPD patients.

Apart from their anti-inflammatory properties, PDE-4 inhibitors have also shown promise in the treatment of other conditions such as depression, cognitive disorders, and autoimmune diseases. Ongoing research and clinical trials aim to explore the full potential of PDE-4 inhibitors in these therapeutic areas.

As with any medication, PDE-4 inhibitors may have certain side effects, including gastrointestinal disturbances (such as diarrhea and nausea), weight loss, and psychiatric effects. Therefore, careful consideration of the risks and benefits is essential before initiating treatment with PDE-4 inhibitors.

In conclusion, PDE-4 inhibitors are a subcategory of pharmaceutical APIs that hold great potential in the treatment of inflammatory and respiratory conditions. With ongoing research and development, these inhibitors may find expanded applications in various therapeutic areas, benefiting patients worldwide.

Roflumilast (Phosphodiesterase-4 Inhibitors), classified under Respiratory Tract Agents

Respiratory Tract Agents are a vital category of pharmaceutical APIs (Active Pharmaceutical Ingredients) designed to treat respiratory conditions and diseases. These agents are specifically formulated to target the respiratory system, which includes the lungs, airways, and nasal passages. They play a crucial role in managing various respiratory disorders, such as asthma, chronic obstructive pulmonary disease (COPD), and allergic rhinitis.

Respiratory Tract Agents encompass a wide range of medications, including bronchodilators, corticosteroids, antihistamines, and mucolytics. Bronchodilators are commonly used to relieve airway constriction and facilitate smooth breathing by relaxing the muscles in the airways. Corticosteroids help reduce inflammation in the respiratory system, alleviating symptoms and preventing exacerbations. Antihistamines work by blocking histamine receptors, thus mitigating allergic reactions that often impact the respiratory tract. Mucolytics aid in loosening and thinning mucus, making it easier to expel from the airways.

These APIs are developed through rigorous research and development processes, ensuring their efficacy, safety, and compliance with regulatory standards. Pharmaceutical manufacturers rely on advanced technologies and stringent quality control measures to produce high-quality Respiratory Tract Agents. These APIs are subsequently incorporated into various dosage forms, including inhalers, nasal sprays, nebulizers, and oral medications.

Respiratory Tract Agents are essential in the management of respiratory conditions, providing relief from symptoms, improving lung function, and enhancing the overall quality of life for patients. They are prescribed by healthcare professionals and often used in combination therapies to achieve optimal results. As respiratory disorders continue to affect a significant portion of the global population, the development and availability of effective Respiratory Tract Agents play a vital role in addressing these health challenges and improving patient outcomes.

• LGM Pharma from United States, product country of origin World
• Shandong Octagon Chemicals Limited from China, product country of origin China
• TIEFENBACHER API + Ingredients from Germany, product country of origin Unknown
• ALP PHARM from China, product country of origin China
• MSN Labs. from India, product country of origin India
• Shaoxing Hantai Pharma from China, product country of origin China
• Mylan from India, product country of origin India
• Hetero Drugs from India, product country of origin India

Let the supplier know whether you are looking for a product with a specific monograph such as EP (Ph. Eur.), USP, JP, BP or another quality. Or, whether you are looking for hydrochloride (HCl), anhydricum, base, micronisatum or a specific purity.

You can use the filters to find high-quality suppliers. For example, you can select GMP, FDA or ISO certified suppliers. Visit our FAQ page or use the chat box in the corner to get more information about Pharmaoffer.